Experimental drug HDP-101 targets Hard-to-Treat myeloma
Disease control
Recruiting now
This study tests an experimental drug, HDP-101, in people with multiple myeloma or related plasma cell disorders. The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments, including stem cell transplant or are not eligible for…
Phase: PHASE1, PHASE2 • Sponsor: Heidelberg Pharma AG • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC